P27; KIP1 Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

P27; KIP1 Polyklonal Antikörper für IF

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

IF

Konjugation

CoraLite® Plus 488 Fluorescent Dye

Kat-Nr. : CL488-25614

Synonyme

CDKN1B, CDKN4, KIP1, MEN1B, MEN4, P27, P27KIP1

---

Galerie der Validierungsdaten

• 

  IF Staining of mouse testis using CL488-25614

  Immunofluorescent analysis of (4% PFA) fixed mouse testis tissue using CoraLite® Plus 488 P27; KIP1 antibody (CL488-25614) at dilution of 1:200.

• 

  IF Staining of mouse testis using CL488-25614

  Immunofluorescent analysis of (4% PFA) fixed mouse testis tissue using CoraLite® Plus 488 P27; KIP1 antibody (CL488-25614) at dilution of 1:200.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF: Maushodengewebe

Empfohlene Verdünnung

• Immunfluoreszenz (IF): IF : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL488-25614 bindet in IF P27; KIP1 und zeigt Reaktivität mit human, Maus

• Getestete Reaktivität: human, Maus
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: P27; KIP1 fusion protein Ag22582
• Vollständiger Name: cyclin-dependent kinase inhibitor 1B (p27, Kip1)
• Berechnetes Molekulargewicht: 198 aa, 22 kDa
• Beobachtetes Molekulargewicht: 27 kDa
• GenBank-Zugangsnummer: BC001971
• Gene symbol: CDKN1B
• Gene ID (NCBI): 1027
• Konjugation: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: BS mit 50% Glyzerin, 0,05% Proclin300, 0,5% BSA, pH 7,3.
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.